S100A4蛋白在甲状腺癌中的表达和意义

 目的 探讨S100A4蛋白在甲状腺癌组织中的表达及临床意义。方法 应用免疫组织化学SP法,检测56例甲状腺癌（乳头状腺癌30例,髓样癌12例,滤泡状癌8例,未分化癌6例）、45例甲状腺良性病变（甲状腺腺瘤、结节性甲状腺肿、原发性甲状腺功能亢进各15例）及13例甲状腺癌癌旁正常组织中S100A4蛋白的表达水平。结果 甲状腺癌组织中S100A4蛋白表达阳性率为83.9%（47/56）,表达强度呈（+）者25例,（++）者12例,（+++）者10例;甲状腺良性病变组织中S100A4蛋白表达阳性率为11.1%（5/45）,表达强度均为（+）;癌旁正常甲状腺组织中S100A4蛋白表达均呈阴性。甲状腺癌组织与后两者比较,差异均具有统计学意义（P<0.01）。临床分期Ⅰ～Ⅱ期者S100A4蛋白表达阳性率为77.8%（28/36）,表达强度为（+）者22例,（++）者4例,（+++）者2例;临床分期Ⅲ～Ⅴ期者表达阳性率为95.0%（19/20）,表达强度为（+）者3例、（++）者8例、（+++）者8例;两者间差异有统计学意义（P<0.01）。有淋巴结转移者S100A4蛋白表达阳性率为100%（16/16）,表达强度为（++）者8例、（+++）者8例;无淋巴结转移者表达阳性率为77.5%（31/40）,表达强度为（+）者25例、（++）者4例、（+++）者2例;两者间差异有统计学意义（P<0.01）。不同病理类型甲状腺癌组织中S100A4蛋白表达阳性率和表达强度差异无统计学意义（P>0.05）。结论 S100A4蛋白表达与甲状腺肿瘤细胞的恶性增殖和侵袭转移密切相关。S100A4蛋白表达强度作为判断甲状腺癌的恶性程度及预后的检测指标,具有临床应用的价值。

Expression and clinical significance of S100A4 protein in human thyroid carcinomas

Objective To study the significance and expression of S100A4 protein in human thyroid gland carcinomas. Methods Immunohistochemistry method was used to detect the expression of S100A4 protein in 56 cases of malignant thyroid gland carcinoma (thyroid papillary cancer in 30 cases, thyroid medullary cancer in 12, thyroid follicular cancer in 8, and anaplastic thyroid cancer in 3), 45 cases of benign thyroid gland tumor (thyroid adenoma in 15, nodular goiter in 15, and primary hyperthyroidism in 15), and 13 cases of normal thyroid gland tissues. Results No S100A4 protein was expressed in normal thyroid gland tissues. The positive expression rate of S100A4 was 83.9% (47/56) in the thyroid gland carcinoma (the intensity of S100A4 protein was "+" in 25 cases, "++" in 12 and "+++" in 10), and 11.1% (5/45) in the benign thyroid gland tumors (the intensity of S100A4 protein was "+" in the 5 cases). There was significant difference in the expression of S100A4 between thyroid gland carcinomas and benign and normal groups (P<0.01). The expression of S100A4 was positively correlated with the clinical stage and lymph node metastasis (P<0.01). The positive expression rate of S100A4 was 77.8% (28/36) at clinical stage Ⅰ-Ⅱ (the intensity of S100A4 protein was "+" in 22 cases, "++" in 4, and "+++" in 2), which was significantly lower than that at clinical stage Ⅲ-Ⅳ 95.0% (19/20, the intensity of S100A4 protein was "+" in 3 cases, "++" in 8, and "+++" in 8, P<0.01). The positive expression rate of S100A4 was 100% (16/16) in the thyroid malignant carcinoma with lymph node metastasis (the intensity of S100A4 protein was "++" in 8 and "+++" in 8 cases), which was significantly higher than that in the thyroid malignant carcinoma without lymph node metastasis 77.5% (31/40, the intensity of S100A4 protein was "+" in 25 cases, "++" in 4, and "+++" in 2, P<0.01). No significant difference was detected in positive rate and the intensity of the expression of S100A4 protein among the tumors with different pathological types. Conclusions S100A4 protein plays an important role in the proliferation and metastasis of thyroid cancer. The intensity of the expression of S100A4 protein can be used to evaluate the malignancy and prognosis of a thyroid cancer.